pivalde, I agree the info from the trial leaves room for guesswork. It is interesting that both BIIB and AstraZenica/Takeda are going directly after A-Syn in the very early stages of the disease(Parkinsons), when A-Syn levels are apparently dropping in the CSF(spinal fluid).
This is still early days with BIIB recruiting phase2 and AZ just starting phase1, but to me it looks like PBT434 has more chance of success, with a wider range of effects, such as those being investigated by the Fairpark2 trial with a related drug. They are not even reporting A-Syn as far as I can see.
All IMO as a non medical observer.
PBT434 inhibits alpha- synuclein in the brain., page-13
Add ATH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.3¢ |
Change
0.000(0.00%) |
Mkt cap ! $15.96M | |||
| Open | High | Low | Value | Volume |
| 0.4¢ | 0.4¢ | 0.3¢ | $3.516K | 1.112M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 75 | 108230584 | 0.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.4¢ | 151421887 | 64 |
View Market Depth
| Last trade - 13.21pm 06/11/2024 (20 minute delay) ? |
| ATH (ASX) Chart |